Data suggest that NKT cells are activated in airways in Idiopathic Pulmonary Fibrosis (IPF) patients and inhibition of iNKT cell activity can treat bleomycin-induced pulmonary fibrosis Company advancing Phase 2a biomarker study of GRI-0621 in patients with IPF with interim data expected Q4 2024 and topline data in Q1 2025 Data presented at the 22nd International Colloquium on Lung and Airway Fibrosis LA JOLLA, CA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a ...

Company continues to advance an innovative pipeline of NKT cell regulators for the treatment of high-value inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced it has received a "Decision to Grant" notice from the Japan Patent ...

Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in a Virtual Investor CEO Connect segment on October 2, 2024 at 12:00 PM ...

Company Overview - GRI Bio is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases by targeting Natural Killer T (NKT) cells [4] - The company's lead program, GRI-0621, is an inhibitor of iNKT cell activity being developed as an oral therapeutic for idiopathic pulmonary fibrosis [4] - GRI Bio is also developing a pipeline of novel type 2 NKT agonists for systemic lupus erythematosus [4] - The company has a library of over 500 proprietary compounds to fuel its pipeline [4] Upcoming Events - Marc Hertz, PhD, CEO of GRI Bio, will present at the H C Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York, NY [1] - Management will be available for one-on-one meetings with qualified investors during the conference [2] - A video webcast of the presentation will be available on-demand starting September 9, 2024 at 7:00 AM ET on the company's website and will be archived for 90 days [3] Technology and Pipeline - GRI Bio's therapies target NKT cells, which are key regulators in the inflammatory cascade, to interrupt disease progression and restore immune system homeostasis [4] - Type 1 invariant (iNKT) cells play a critical role in propagating injury, inflammatory response, and fibrosis in inflammatory and fibrotic diseases [4] - The company's approach aims to fundamentally change the treatment of inflammatory, fibrotic, and autoimmune diseases [4]

LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 European Respiratory Congress (ERS) being held September 7-11, 2024 in Vienna, Austria. Details of the poster presentation are as follows: Title: T ...

NASDAQ: GRI | gribio.com U l A New Ap Inflammator August Corporate P Forward Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of GRL Bio, Inc. ("GRI" or the "Company This presentation contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Liligation Reform Act of 1995. Forward- of words such as "anticipate," "believe," "contemplate," "could," "est ...

Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and topline data on track for Q1 2025 LA JOLLA, CA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today repo ...

Table of Contents ____________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRA ...

ST HELIER, Jersey, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Caledonia Mining Corporation Plc ("Caledonia" or "the Company") (NYSE AMERICAN, AIM and VFEX: CMCL) announces the publication of its 2023 ESG Report. The full report is available on the Company's website at www.caledoniamining.com/esg/esg-reports/. Caledonia has enhanced its sustainability reporting to align with the Global Reporting Initiative (GRI) and Sustainability Accounting Standards Board (SASB) standards for the first time. This reflects the Compa ...

LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio," "we," "our," or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024 at 12:00 PM ET. About GRI Bio, Inc. Live video webcast on Wednesday, July 17th at 12:00 PM ET A live video webcast of the p ...